VIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards

VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma,  and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel.   Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…

Read More

First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers

Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…

Read More

Aussie men with advanced prostate cancer denied access to innovative treatment on Medicare

Almost 20,000 Australian men diagnosed each year with prostate cancer are being denied access to an innovative treatment on Medicare for the nation’s most common cancer in men. Two treatment options – low dose rate brachytherapy (LDR-brachytherapy) and external beam radiation therapy – are approved to treat prostate cancer in Australia by the medical regulator,…

Read More

State Health authorities issues public health warnings following identification of mosquito-borne virus

Three State Health authorities have this week issued public health warnings following the identification of the Japanese encephalitis (JE) virus in samples gathered from pig farms in New South Wales, Queensland, and Victoria. Common to Asia and the west Pacific, and rural and agricultural regions, the JE virus is spread through the bite of infected…

Read More